APOE p.Leu167del mutation in familial hypercholesterolemia

Atherosclerosis

Volumn 231, Issue 2, 2013, Pages 218-222

  Awan, Zuhier ^a,b   Choi, Hong Y ^a   Stitziel, Nathan ^c   Ruel, Isabelle ^a   Bamimore, Mary Aderayo ^d   Husa, Regina ^a   Gagnon, Marie Helene ^a   Wang, Rui Hao L ^a   Peloso, Gina M ^e   Hegele, Robert A ^d   Seidah, Nabil G ^b   Kathiresan, Sekar ^e   Genest, Jacques ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

APOE gene; Autosomal dominant hypercholesterolemia; Familial hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR ADAPTER PROTEIN 1; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ALPHA HELIX; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 19; CHROMOSOME MUTATION; DNA SEQUENCE; EXOME; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ASSOCIATION; GEOGRAPHIC ORIGIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MYALGIA; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

APOE GENE; AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA; FAMILIAL HYPERCHOLESTEROLEMIA;

ADULT; APOLIPOPROTEINS B; APOLIPOPROTEINS E; CHOLESTEROL, LDL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LEUCINE; LIGANDS; MALE; MUTATION; MYOCARDIAL INFARCTION; PEDIGREE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; RISK; SEQUENCE ANALYSIS, DNA; SERINE ENDOPEPTIDASES; XANTHOMATOSIS;

EID: 84888110440     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.09.007     Document Type: Article

References (29)

1. Talmud P.J., Shah S., Whittall R., et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013 Apr 13, 381(9874):1293-1301.
2. Rader D.J., Cohen J., Hobbs H.H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. JClin Invest 2003 Jun, 111(12):1795-1803.
3. Vega G.L., Grundy S.M. Invivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. JClin Invest 1986 Nov, 78(5):1410-1414.
4. Abifadel M., Varret M., Rabès J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 Jun, 34(2):154-156.
5. Seidah N.G. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des 2013 Jan.
6. Filigheddu F., Quagliarini F., Campagna F., et al. Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. Atherosclerosis 2009 Nov, 207(1):162-167.
7. Marduel M., Carrié A., Sassolas A., et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 2010 Nov, 31(11):E1811-E1824.
8. Asselbergs F.W., Guo Y., van Iperen E.P., et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012 Nov 2, 91(5):823-838.
9. Herz J., Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006, 7:850-859.
10. Johansen C.T., Kathiresan S., Hegele R.A. Genetic determinants of plasma triglycerides. JLipid Res 2011, 52:189-206.
11. Tsimihodimos V., Elisaf M. Lipoprotein glomerulopathy. Curr Opin Lipidol 2011, 22(4):262-269.
12. Marduel M., Ouguerram K., Serre V., et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 2013 Jan, 34(1):83-87.
13. Reddy M.V., Iatan I., Weissglas-Volkov D., et al. Exome sequencing identifies 2 rare variants for low high-density lipoprotein cholesterol in an extended family. Circ Cardiovasc Genet 2012 Oct 1, 5(5):538-546.
14. PolyPhen-2 prediction of functional effects of human nsSNPs. Web site. [accessed January 2013]. http://genetics.bwh.harvard.edu/pph2.
15. The J. Craig Venter Institute. The SIFT web site. [accessed January 2013]. http://www.jcvi.org.
16. The J. Craig Venter Institute. Protein Variation Effect Ananlyzer (PROVEAN) web site. [accessed January 2013]. http://www.provean.jcvean.org.
17. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform 2008, 9(40).
18. The PyMOL Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC. Web site. [accessed January 2013]. http://www.pymol.org.
19. Anderson T.J., Grégoire J., Hegele R.A., et al. Society guidelines 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. 2012 recommendations. Can J Cardiol 2013, 29(2):151-167.
20. Ye Z.J., Go G.W., Singh R., et al. LRP6 protein regulates low density lipoprotein (LDL) receptor-mediated LDL uptake. JBiol Chem 2012, 287(2):1335e44.
21. Nguyen T., Kruckeberg E., O'Brien F., et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 leu)]. JClin Endocr Metab 2000, 85:4354-4358.
22. Faivre L., Saugier-Veber P., Pais de Barros J.P., et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. Eur J Hum Genet 2005 Nov, 13(11):1186-1191.
23. Solanas-Barca M., de Castro-Orós I., Mateo-Gallego R., et al. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis 2012 Jun, 222(2):449-455.
24. Brouwers C., van Greevenbroek M., Stehouwer D., et al. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol 2012 Feb 14, 8(6):352-356.
25. Hatters M., Peters-Libeu A., Weisgraber H. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006 Aug, 31(8):445-454.
26. Wang J., Ban M.R., Hegele R.A. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. JLipid Res 2005 Feb, 46(2):366-372.
27. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999 Jan, 142(1):105-112.
28. Hansen P.S., Defesche J.C., Kastelein J.J., et al. Phenotypic variation in patients heterozygous for familial defective apolipoprotein B (FDB) in three European countries. Arterioscler Thromb Vasc Biol 1997 Apr, 17(4):741-747.
29. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2005 Jul, 25(7):1475-1481.